BRWM
IMDX

B. Riley Wealth Management’s Insight Molecular Diagnostics IMDX Stock Holding History

B. Riley Wealth Management’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		$13 Hold
750
– – ﹤0.01% 749
2022
Q1 		$22K Hold
750
– – ﹤0.01% 620
2021
Q4 		$33K Buy
750
+50
+7% +$2.88K ﹤0.01% 650
2021
Q3 		$50K Buy
+700
New +$64.3K ﹤0.01% 626

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return

B. Riley Wealth Management's IMDX Position: Q2 2022 in Review

B. Riley Wealth Management held its Insight Molecular Diagnostics (IMDX) position steady in Q2 2022 at 750 shares worth $13. The position accounts for ﹤0.01% of the portfolio, ranked #749.

B. Riley Wealth Management first reported a position in IMDX in Q3 2021 and has held it in 4 quarters since. The position peaked at $50K in Q3 2021. 75 funds tracked by Wall St. Rank hold IMDX as of Q2 2022.

  • B. Riley Wealth Management held 750 shares of Insight Molecular Diagnostics worth $13 as of Q2 2022.
  • B. Riley Wealth Management left its Insight Molecular Diagnostics share count unchanged in Q2 2022.
  • Insight Molecular Diagnostics made up ﹤0.01% of B. Riley Wealth Management's portfolio in Q2 2022, its #749 holding.
  • B. Riley Wealth Management first reported a position in Insight Molecular Diagnostics in Q3 2021 and has held it in 4 quarters since.
  • B. Riley Wealth Management's Insight Molecular Diagnostics position peaked at $50K in Q3 2021.
  • 75 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q2 2022.

Based on B. Riley Wealth Management's 13F filing for Q2 2022, filed 9 Sep 2022.